Certara, Inc. (NASDAQ:CERT) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue cut its position in Certara, Inc. (NASDAQ:CERTFree Report) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 200,916 shares of the company’s stock after selling 765 shares during the period. State of Alaska Department of Revenue owned 0.13% of Certara worth $3,533,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in CERT. Raymond James & Associates boosted its stake in shares of Certara by 83.4% in the first quarter. Raymond James & Associates now owns 37,080 shares of the company’s stock worth $796,000 after acquiring an additional 16,861 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Certara by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 384,913 shares of the company’s stock worth $8,268,000 after acquiring an additional 4,107 shares during the last quarter. HighTower Advisors LLC boosted its stake in Certara by 71.6% during the first quarter. HighTower Advisors LLC now owns 19,847 shares of the company’s stock worth $440,000 after buying an additional 8,282 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Certara by 18.3% during the first quarter. PNC Financial Services Group Inc. now owns 5,841 shares of the company’s stock worth $126,000 after buying an additional 905 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new position in Certara during the first quarter worth $111,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Richard M. Traynor sold 6,000 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $18.00, for a total value of $108,000.00. Following the transaction, the senior vice president now owns 165,368 shares in the company, valued at approximately $2,976,624. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CERT shares. Leerink Partnrs reissued a “market perform” rating on shares of Certara in a research note on Monday, February 26th. Barclays upped their price target on Certara from $16.00 to $18.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. SVB Leerink initiated coverage on Certara in a research note on Monday, February 26th. They issued a “market perform” rating and a $19.00 price target on the stock. UBS Group upped their price target on Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, March 1st. Finally, Jefferies Financial Group upped their price target on Certara from $14.00 to $15.50 and gave the company a “hold” rating in a research note on Friday, March 1st. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Certara currently has a consensus rating of “Hold” and a consensus price target of $19.64.

View Our Latest Analysis on Certara

Certara Price Performance

Shares of NASDAQ CERT opened at $16.95 on Wednesday. The stock’s 50-day moving average is $17.55 and its two-hundred day moving average is $15.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.62 and a quick ratio of 2.62. Certara, Inc. has a 1-year low of $11.81 and a 1-year high of $24.96. The company has a market cap of $2.71 billion, a price-to-earnings ratio of -48.43, a price-to-earnings-growth ratio of 1.83 and a beta of 1.63.

Certara (NASDAQ:CERTGet Free Report) last issued its quarterly earnings results on Thursday, February 29th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.04). Certara had a positive return on equity of 4.33% and a negative net margin of 15.62%. The company had revenue of $88.01 million for the quarter, compared to analysts’ expectations of $86.80 million. Analysts forecast that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Certara Company Profile

(Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Further Reading

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERTFree Report).

Institutional Ownership by Quarter for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.